Joint Symposium on Medicinal Chemistry
Boston, MA, United States June 10-13, 2023
Optional excursions
Registration
Opening of the Symposium and Welcome address
PL01- Medicinal Chemistry, Trends, Targets and Technologies
Welcome Reception
Registration
Session chair
IL01 - Modulating the Conformation and Function of Disease-Relevant RNA with Small Molecules
IL02 - Targeting Non-Coding RNAs Using Synthetic Small Molecules: Original Targets for Innovative Therapies
IL03 - Discovery and Development of Selective Splicing Modifiers as Therapeutics
OC01
Coffee break & Exhibition
Session chair
IL04 - Ligand Directed Degradation: from Proof-of-Concept Degradation to Clinical Studies
IL05 - Chemical Biology Studies of the Thalidomide-Binding Domain of Cereblon
OC02
OC03
Lunch & Exhibition
Session chair
IL06 -Chemoproteomic-Enabled Development of Proximity-Inducing Molecules
IL07 - An Intramolecular Bivalent Degrader Glues an Intrinsic BRD4-DCAF16 Interaction
OC04
OC05
Coffee break & Exhibition
PL02 - RIPTACs: A New ‘Hold and Kill’-based Therapeutic Modality
Poster session 1 (odd numbers)
End of the day
Session chair
IL08 - New Hot Targets? Medicinal Chemistry of G Protein-Coupled Receptors Involved in Immunity and Cancer
IL09 - Frontier SBDD accross the Orthosteric and Allosteric GPCRome
OC06
OC07
Coffee break & Exhibition
Session chair
IL10 - Photocatalysis in the Pharmaceutical Industry: Synthesis under a New Light
IL11 - HTE Chemistry to Accelerate Medicinal Chemistry Programs
OC08
OC09
Lunch & Exhibition
Session chair
IL12 - Chemical Probes Enabling Drug Target Discovery and Validation
IL13 - Generating Stem-Like T Cells with Small-Molecule Modulators for Cancer Immunotherapy
OC10
OC11
Coffee break & Exhibition
Poster session 2 (even numbers)
Session chair
IL15 - Chemical Approaches to Enhance Cellular Immunotherapies
IL16 - Machine Learning Tools to Accelerate Chemical Biology Studies
OC12
OC13
OC14
Coffee break & Exhibition
Session chair
IL17 - A Computation-First Approach to Drug Challenging Disease Targets
IL18 - X-ray Crystallographic Fragment Screening for the Identification of Allosteric binding Sites
OC15
OC16
Lunch & Exhibition
Session chair
IL19 - RAPID – a Next-Generation Chemoproteomics Technology Enabling the Discovery of Reversible Binders to Pre-specified Targets in Living Cells
IL20 - Covalent Fragment-Based Drug Discovery
IL21 - Large-scale in Silico Fragment Screening of ~200 Million Fragments Based on Absolute Free Energy Perturbation
OC17
End of the Symposium